Journal article
Fetal Serotonin Reuptake Inhibitor Antidepressant Exposure: Maternal and Fetal Factors
Abstract
Prenatal serotonin reuptake inhibitor exposure is common and neonatal outcomes vary greatly, often leading to confusion about whether to use or even continue antenatal use of these antidepressants. Importantly, some but not all infants are affected, which raises questions about how maternal drug metabolism contributes to fetal drug exposure. To address this key question, our paper reviews the role of key maternal, fetal, and placental …
Authors
Shea AK; Oberlander TF; Rurak D
Journal
The Canadian Journal of Psychiatry, Vol. 57, No. 9, pp. 523–529
Publisher
SAGE Publications
Publication Date
9 2012
DOI
10.1177/070674371205700902
ISSN
0706-7437
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Antidepressive AgentsBiological AvailabilityCytochrome P-450 Enzyme SystemDepressive DisorderFemaleFetusGenome-Wide Association StudyHumansInactivation, MetabolicMaternal-Fetal ExchangePharmacogeneticsPregnancyPregnancy ComplicationsPrenatal Exposure Delayed EffectsRisk AssessmentSelective Serotonin Reuptake Inhibitors